Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes Obesity and Metabolism(2025)10.1111/dom.16469Source: DataRank Database

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications is a research paper published in Diabetes Obesity and Metabolism (2025). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

refsnp nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (30 grants)Impact (FWCI 9.85)OA: hybridTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Harpreet Bhatia ORCID,Roger S. Blumenthal ORCID,Michael D. Shapiro ORCID,Anurag Mehta ORCID,Alexander C. Razavi ORCID

Live enrichment

PubMed:40437821 PMC:PMC12354239 OpenAlex:https://openalex.org/W4410871301

NIH HHS

Grant: 1K08HL166962

NHLBI NIH HHS

Grant: F32 HL172499

NHLBI NIH HHS

Grant: K08 HL166962

NHLBI NIH HHS

Grant: L30 HL175751

89Bio

Arrowhead Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals, Inc.

Cleerly

Arrowhead

NewAmsterdam Pharma

89bio

Ionis Pharmaceuticals

Lilly

Merck

Amgen

Esperion

Novartis

Boehringer Ingelheim

Esperion Therapeutics

Arrowhead

Lilly

Ionis Pharmaceuticals

Merck

Boehringer Ingelheim Pharmaceuticals, Inc.

NewAmsterdam Pharma

Cleerly

Novartis

89Bio

Amgen

Esperion

FWCI

9.85

Citation Percentile

1.0%

Influential Citations

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16469

HYBRIDhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16469

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16469

journalhttps://doi.org/10.1111/dom.16469

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40437821

Fields of Study

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesAntiplatelet Therapy and Cardiovascular DiseasesMedicineHumansLipoprotein(a)AtherosclerosisAortic Valve StenosisCardiovascular DiseasesAortic ValveCalcinosisRisk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorsAortic Valve, Calcification of

MeSH Terms

Aortic ValveAortic Valve StenosisCalcinosisCardiovascular DiseasesHumansRisk FactorsLipoprotein(a)Hydroxymethylglutaryl-CoA Reductase InhibitorsAtherosclerosis

Keywords

MedicineDiseaseAtherosclerotic cardiovascular diseaseLipoprotein(a)StatinGuidelineIntensive care medicineFamilial hypercholesterolemiaRisk factorPCSK9EpidemiologyNarrative reviewBioinformaticsInternal medicineLipoproteinPathologyCholesterolLDL receptorCardiovascular diseaseDyslipidaemiaMacrovascular DiseaseLipid‐lowering Therapy

Sustainable Development Goals

SDG 0: Good health and well-being

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

FAIR Checklist

Authors (5)

Funding (30 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)